Title: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
Headings: Staphylococcus saprophyticus
: Which beta-lactam?

International Journal of Infectious Diseases
Short Communication
Staphylococcus saprophyticus: Which beta-lactam?
Highlights
Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
Methods
Results
Discussion
Conflict of interest/funding
References

Content: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
International Journal of Infectious Diseases
Volume 65, December 2017, Pages 63-66
Short Communication
Staphylococcus saprophyticus: Which beta-lactam? Author links open overlay panel
HélènePailhoriès VivianeCassisa RachelChenouard Marie Kempf MatthieuEveillard CaroleLemarié
Outline
https://doi.org/10.1016/j.ijid.2017.10.001 Get rights and content
Under a Creative Commons license
open access
Highlights
•
The treatment of Staphylococcus saprophyticus urinary tract infections is difficult. •
This study analysed the epidemiology of S. saprophyticus urinary tract infections. •
Susceptibility of S. saprophyticus to ceftriaxone was studied. •
A high rate of ineffective empirical antibiotic therapy for S. saprophyticus was noted. •
High ceftriaxone minimum inhibitory concentrations were noted for methicillin-susceptible S. saprophyticus. Abstract
Background
Staphylococcus saprophyticus is resistant to the drugs most often used for the empirical treatment of urinary tract infections (UTI).